CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
CorMedix Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.38+0.12 (+1.65%)
Close on Oct 19, 2026
- Market cap
- $682.50M
- P/E (TTM)
- 3.6
- Dividend yield
- –
CorMedix Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q4 21 | Q4 20 | Q4 19 | Q4 18 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $94.34M | $121.92M | $123.98M | $101.55M | $39.74M | $39.08M | $31.21M | $11.46M | – | – | – | – | 92.6% | +137.4% |
| Defen Cath | $66.12M | $97.51M | $91.23M | $88.77M | $39.74M | $39.08M | $31.21M | $11.46M | – | – | – | – | 64.9% | +66.4% |
| Melinta Portfolio | $28.22M | $24.41M | $32.75M | $12.78M | $0 | $0 | – | – | – | – | – | – | 27.7% | – |
| Contract revenue | $4.97M | $5.51M | $4.64M | $2.73M | $0 | $0 | – | – | – | – | – | – | 4.9% | – |
| Grant income | $2.62M | – | – | – | $0 | – | – | – | – | – | – | – | 2.6% | – |
By region
From the segment and revenue-disaggregation notes of CorMedix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.